Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan vs dobutamine for septic cardiomyopathy microcirculation
ChiCTR2300077876Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levosimendan in septic cardiomyopathy (SCM), sepsis and septic shock (2 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Left ventricular ejection fraction and Myocardial blood flow. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
septic cardiomyopathy (SCM)sepsisseptic shock
Beyond the preview
Go deeper on ChiCTR2300077876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077876.